EEG
TCRT icon

E.E. Geduld’s Alaunos Therapeutics TCRT Stock Holding History

E.E. Geduld’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-67
Closed -$108K – 309
2015
Q1 		$108K Buy
+67
New +$99.3K 0.07% 193
2013
Q4 		– Sell
-167
Closed -$99K – 343
2013
Q3 		$99K Buy
167
+56
+50% +$25.2K 0.06% 216
2013
Q2 		$35K Buy
+111
New +$30.8K 0.02% 233

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $423M AUM 49.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

E.E. Geduld's TCRT Position: Q4 2016 in Review

E.E. Geduld held its Alaunos Therapeutics (TCRT) position steady in Q4 2016 at 67 shares worth $54K. The position accounts for 0.03% of the portfolio, ranked #132.

E.E. Geduld first reported a position in TCRT in Q3 2013 and has held it in 12 quarters since. The position peaked at $809K in Q1 2015. 136 funds tracked by Wall St. Rank hold TCRT as of Q4 2016.

  • E.E. Geduld held 67 shares of Alaunos Therapeutics worth $54K as of Q4 2016.
  • E.E. Geduld left its Alaunos Therapeutics share count unchanged in Q4 2016.
  • Alaunos Therapeutics made up 0.03% of E.E. Geduld's portfolio in Q4 2016, its #132 holding.
  • E.E. Geduld first reported a position in Alaunos Therapeutics in Q3 2013 and has held it in 12 quarters since.
  • E.E. Geduld's Alaunos Therapeutics position peaked at $809K in Q1 2015.
  • 136 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2016.

Based on E.E. Geduld's 13F filing for Q4 2016, filed 8 Feb 2017.